Bank of Stockton Has $551,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Bank of Stockton lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,931 shares of the company’s stock after selling 220 shares during the period. Bank of Stockton’s holdings in Novo Nordisk A/S were worth $551,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Victory Capital Management Inc. boosted its position in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after purchasing an additional 23,223 shares during the period. North Star Investment Management Corp. grew its stake in Novo Nordisk A/S by 18.2% in the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company’s stock valued at $1,440,000 after buying an additional 3,200 shares during the last quarter. Stanley Laman Group Ltd. bought a new position in Novo Nordisk A/S in the 1st quarter worth $390,000. Dover Advisors LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $505,000. Finally, SVB Wealth LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $1,250,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 4.8%

Shares of NVO stock opened at $67.37 on Thursday. The firm has a fifty day moving average of $68.70 and a 200-day moving average of $77.86. The stock has a market cap of $300.81 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 1.26 and a beta of 0.66. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $145.99. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on NVO shares. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Finally, Wall Street Zen raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.